We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Phase 3 Remdesivir Data Shows Uncertain Benefits in Moderately Ill COVID-19 Patients
Phase 3 Remdesivir Data Shows Uncertain Benefits in Moderately Ill COVID-19 Patients
New data from Gilead Sciences’ late-stage trial of its antiviral remdesivir showed that a five-day course of the drug helped patients with moderate COVID-19 pneumonia, but the finding was of “uncertain clinical importance,” according to researchers.